In:
Journal of Hepato-Biliary-Pancreatic Sciences, Wiley, Vol. 28, No. 6 ( 2021-06), p. 524-532
Abstract:
The relationship between autoimmune pancreatitis (AIP) and malignancy has been reported. However, the potential risk for cancer in patients with immunoglobulin 4 (IgG4)‐related sclerosing cholangitis (IgG4‐SC) is unclear. The present study aimed to evaluate the incidence of cancer in IgG4‐SC patients. Methods We retrospectively collected clinical data for 121 patients diagnosed with IgG4‐SC from 7 hospitals. We calculated the standardized incidence ratio (SIR) of cancer in IgG4‐SC patients based on the national cancer rates. The SIR of the period after the diagnosis of IgG4‐SC were calculated. Results The mean follow‐up period was 6.4 years, with 121 IgG4‐SC patients. During the follow‐up period, 26 patients had cancer, and 29 cancers were diagnosed. The SIR of cancer after the diagnosis of IgG4‐SC was 1.90 (95% confidence interval [CI] 1.67‐2.21). The SIR of pancreatic and bile duct cancer was 10.30 and 8.88, respectively. The SIR of cancer in 〈 1 year, 1‐5 years, and 〉 5 years after diagnosis of IgG4‐SC were 2.58, 1.01, and 2.44, respectively. Conclusions IgG4‐SC patients have a high risk of cancer including pancreatic and bile duct cancer. The risk of cancer was high less 〈 1 year and 〉 5 years after diagnosis of IgG4‐SC. Therefore, IgG4‐SC patients may require careful long‐term follow‐up.
Type of Medium:
Online Resource
ISSN:
1868-6974
,
1868-6982
Language:
English
Publisher:
Wiley
Publication Date:
2021
detail.hit.zdb_id:
2536390-6
Bookmarklink
